Clinical course and disease outcome in patients with severe COVID-19 receiving remdesivir

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

RAEISI AHMAD; REZAEI ZAHRA; HABIBI ZAHRA; SALIMI MARYAM; RAEISI HADI

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Journal of Shahrekord University of Medical Sciences Year:2022 | Volume:24 | Issue:1 Page(s): 7-14

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Clinical course and disease outcome in patients with severe COVID-19 receiving remdesivir

Author(s)

Keywords

COVID-19

Treatment

Hospitalization

Abstract

Background and aims: COVID-19 is a pandemic and infectious disease with high morbidity and mortality rates as well as a global spread. This study aimed to investigate the clinical outcomes for patients afflicted with COVID-19 and treated with remdesivir. Methods: In this clinical trial study, patients with severe COVID-19 confirmed by molecular testing and hospitalized at Hajar Hospital of Shahrekord in Iran were divided into standard care group (including 52 patients) and standard + remdesivir group (including 51 patients). The patients were examined for clinical symptoms, laboratory data, as well as mortality and recovery rates during the Treatment period. Then the data were analyzed by SPSS version 23 using chi-square, independent t-test and repeated-measures ANOVA. Result: Clinical and laboratory monitoring on days 5, 10, and 14 showed that there was no significant difference between two groups (P > 0. 05). In addition, there was no significant difference between the two groups in terms of Hospitalization duration and ICU rate (58. 8% versus 51. 9%, P = 0. 48). The trend of Lymph count and platelet decreased significantly in the standard group (P = 0. 003, P = 0. 04, and P = 0. 03, respectively). Conclusion: Patients with severe COVID-19 were investigated and it was concluded that remdesivir produced no improvement in the remdesivir group compared to the standard group.

Cites

References

Cite

APA: Copy

RAEISI, AHMAD, REZAEI, ZAHRA, HABIBI, ZAHRA, SALIMI, MARYAM, & RAEISI, HADI. (2022). Clinical course and disease outcome in patients with severe COVID-19 receiving remdesivir. JOURNAL OF SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES, 24(1), 7-14. SID. https://sid.ir/paper/1002745/en

Vancouver: Copy

RAEISI AHMAD, REZAEI ZAHRA, HABIBI ZAHRA, SALIMI MARYAM, RAEISI HADI. Clinical course and disease outcome in patients with severe COVID-19 receiving remdesivir. JOURNAL OF SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES[Internet]. 2022;24(1):7-14. Available from: https://sid.ir/paper/1002745/en

IEEE: Copy

AHMAD RAEISI, ZAHRA REZAEI, ZAHRA HABIBI, MARYAM SALIMI, and HADI RAEISI, “Clinical course and disease outcome in patients with severe COVID-19 receiving remdesivir,” JOURNAL OF SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES, vol. 24, no. 1, pp. 7–14, 2022, [Online]. Available: https://sid.ir/paper/1002745/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops